Tezosentan
- Generic Name
- Tezosentan
- Brand Names
- -
- Drug Type
- Small Molecule
- Chemical Formula
- C27H27N9O6S
- CAS Number
- 180384-57-0
- Unique Ingredient Identifier
- 64J9J55263
- Background
Tezosentan is an intravenous endothelin receptor A/B antagonist. Tezosentan was initially developed for vasodilation in patients with acute heart failure but studies have shown that it does not assist in the treatment of dyspnea or prevent cardiovascular events.
- Indication
Investigated for use/treatment in congestive heart failure, liver disease, and heart disease.
- Associated Conditions
- -
- Associated Therapies
- -
Tezosentan in Pulmonary Arterial Hypertension
- First Posted Date
- 2010-03-01
- Last Posted Date
- 2018-07-09
- Lead Sponsor
- Idorsia Pharmaceuticals Ltd.
- Target Recruit Count
- 3
- Registration Number
- NCT01077297
- Locations
- 🇺🇸
Washington University School of Medicine, Saint Louis, Missouri, United States
🇺🇸Baylor College of Medicine, Houston, Texas, United States
🇫🇷Hopital Antoine Béclère, Paris, Clamart, France
Tezosentan in Acute Heart Failure
- Conditions
- Interventions
- First Posted Date
- 2007-09-06
- Last Posted Date
- 2018-07-10
- Lead Sponsor
- Idorsia Pharmaceuticals Ltd.
- Target Recruit Count
- 735
- Registration Number
- NCT00525707
- Locations
- 🇨ðŸ‡
Cardio Centro Ticino, Servizio Cardiovasculare, Lugano, Switzerland
🇵🇱Kategra I Klinika Kardiolgii AM, Wroclaw, Poland
🇺🇸Denver VAMC, Denver, Colorado, United States
Tezosentan in the Treatment of Acute Heart Failure
- Conditions
- Interventions
- First Posted Date
- 2007-09-03
- Last Posted Date
- 2018-07-10
- Lead Sponsor
- Idorsia Pharmaceuticals Ltd.
- Target Recruit Count
- 713
- Registration Number
- NCT00524433
- Locations
- 🇺🇸
Oracle Research, Huntsville, Alabama, United States
🇺🇸USC Medical Center, Los Angeles, California, United States
🇺🇸Jacksonville Center for Clinical Research, Jacksonville, Florida, United States
Study of the Efficacy and Safety of Tezosentan in Patients With Pre-operative Pulmonary Hypertension, Due to Left Heart Disease, Undergoing Open Heart Surgery
- Conditions
- Interventions
- First Posted Date
- 2007-04-10
- Last Posted Date
- 2018-07-09
- Lead Sponsor
- Idorsia Pharmaceuticals Ltd.
- Target Recruit Count
- 274
- Registration Number
- NCT00458276
- Locations
- 🇨🇦
University of Alberta Hospital, Edmonton, Alberta, Canada
🇨🇦London Health Sciences Centre-University Hospital, London, Ontario, Canada
🇺🇸Columbia University Medical Center, New York, New York, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.